Yin Qiu Tan1, Yun Tao Li1, Teng Feng Yan1, Yang Xu1, Bao Hui Liu1, Ji An Yang1, Xue Yang1, Qian Xue Chen1, Hong Bo Zhang2,3. 1. Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China. 2. Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 3. The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Guangzhou, China.
Abstract
Background: The immunotherapy of Glioma has always been a research hotspot. Although tumor associated microglia/macrophages (TAMs) proves to be important in glioma progression and drug resistance, our knowledge about how TAMs influence glioma remains unclear. The relationship between glioma and TAMs still needs further study. Methods: We collected the data of TAMs in glioma from NCBI Gene Expression Omnibus (GEO) that included 20 glioma samples and 15 control samples from four datasets. Six genes were screened from the Differential Expression Gene through Gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, protein-protein interaction (PPI) network and single-cell sequencing analysis. A risk score was then constructed based on the six genes and patients' overall survival rates of 669 patients from The Cancer Genome Atlas (TCGA). The efficacy of the risk score in prognosis and prediction was verified in Chinese Glioma Genome Atlas (CGGA). Results: Six genes, including CD163, FPR3, LPAR5, P2ry12, PLAUR, SIGLEC1, that participate in signal transduction and plasma membrane were selected. Half of them, like CD163, FPR3, SIGLEC1, were mainly expression in M2 macrophages. FPR3 and SIGLEC1 were high expression genes in glioma associated with grades and IDH status. The overall survival rates of the high risk score group was significantly lower than that of the low risk score group, especially in LGG. Conclusion: Joint usage of the 6 candidate genes may be an effective method to diagnose and evaluate the prognosis of glioma, especially in Low-grade glioma (LGG).
Background: The immunotherapy of Glioma has always been a research hotspot. Although tumor associated microglia/macrophages (TAMs) proves to be important in glioma progression and drug resistance, our knowledge about how TAMs influence glioma remains unclear. The relationship between glioma and TAMs still needs further study. Methods: We collected the data of TAMs in glioma from NCBI Gene Expression Omnibus (GEO) that included 20 glioma samples and 15 control samples from four datasets. Six genes were screened from the Differential Expression Gene through Gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, protein-protein interaction (PPI) network and single-cell sequencing analysis. A risk score was then constructed based on the six genes and patients' overall survival rates of 669 patients from The Cancer Genome Atlas (TCGA). The efficacy of the risk score in prognosis and prediction was verified in Chinese Glioma Genome Atlas (CGGA). Results: Six genes, including CD163, FPR3, LPAR5, P2ry12, PLAUR, SIGLEC1, that participate in signal transduction and plasma membrane were selected. Half of them, like CD163, FPR3, SIGLEC1, were mainly expression in M2 macrophages. FPR3 and SIGLEC1 were high expression genes in glioma associated with grades and IDH status. The overall survival rates of the high risk score group was significantly lower than that of the low risk score group, especially in LGG. Conclusion: Joint usage of the 6 candidate genes may be an effective method to diagnose and evaluate the prognosis of glioma, especially in Low-grade glioma (LGG).
Authors: L Lisi; G M P Ciotti; D Braun; S Kalinin; D Currò; C Dello Russo; A Coli; A Mangiola; C Anile; D L Feinstein; P Navarra Journal: Neurosci Lett Date: 2017-03-02 Impact factor: 3.046
Authors: Zinal S Chheda; Gary Kohanbash; Kaori Okada; Naznin Jahan; John Sidney; Matteo Pecoraro; Xinbo Yang; Diego A Carrera; Kira M Downey; Shruti Shrivastav; Shuming Liu; Yi Lin; Chetana Lagisetti; Pavlina Chuntova; Payal B Watchmaker; Sabine Mueller; Ian F Pollack; Raja Rajalingam; Angel M Carcaboso; Matthias Mann; Alessandro Sette; K Christopher Garcia; Yafei Hou; Hideho Okada Journal: J Exp Med Date: 2017-12-04 Impact factor: 14.307
Authors: Andrew S Gilder; Letizia Natali; Danielle M Van Dyk; Cristina Zalfa; Michael A Banki; Donald P Pizzo; Huawei Wang; Richard L Klemke; Elisabetta Mantuano; Steven L Gonias Journal: Sci Rep Date: 2018-02-14 Impact factor: 4.379
Authors: Grazia Menna; Pier Paolo Mattogno; Carlo Maria Donzelli; Lucia Lisi; Alessandro Olivi; Giuseppe Maria Della Pepa Journal: Brain Sci Date: 2022-05-31